Alectinib ALUR



Alectinib ALUR Alectinib ALUR PRELIMINARY SCORE **SCORE** CURATIVE **CURATIVE** Overall Survival / Disease-Free Survival / Pathological Complete Response **NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life Progression-Free Survival QoL data pending Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Less serious and disabling adverse events observed Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Other adjustments Tumour type: Thoracic Malignancies Therapeutic Indication: As monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib Experimental Arm: Alectinib Control Arm: Chemotherapy (pemetrexed or docetaxel)



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.